Urine calcium and deoxypyridinoline in assessment of response to local radiation therapy for metastatic bone disease

Basit Öğe Kaydı
dc.authoridTopkan, Erkan/0000-0001-8120-7123;
dc.authorwosidTopkan, Erkan/AAG-2213-2021
dc.authorwosidKaraoglu, Aziz/HKM-3509-2023
dc.contributor.authorTopkan, E.
dc.contributor.authorKaraoglu, A.
dc.date.accessioned2024-08-04T20:30:39Z
dc.date.available2024-08-04T20:30:39Z
dc.date.issued2007
dc.departmentİnönü Üniversitesien_US
dc.description.abstractTo evaluate the predictability of urine calcium (Ca2+) and deoxypyridinoline (DPD) in the assessment of response to palliative radiation therapy (RT) for metastatic bone disease. Forty-two patients with osteolytic bone metastases from breast or lung primaries were enrolled in this study. Serial urine Ca2+ and DPD measurements were performed before RT, six weeks, and twelve weeks afterwards. All eligible patients received a total of 30 Gy RT in 3 Gy daily fractions. Pre-irradiation mean urine Ca+2 and DPD levels were 16 +/- 3.7 g/mu mol/dL, and 89.2 +/- 61 pmol/mu mol crea. Both were significantly higher than normal range. A significant correlation between pre-irradiation Ca+2 (r=0.6, p<0.001), DPD (r=0.8, p<0.001) levels and the extent of bone metastases were detected. Thirty-six patients (Group I) were alive without disease progression outside the radiation portal. Urine Ca2+ and DPD levels demonstrated a significant and progressive decrease following RT in Group I patients (p<0.001). Clinical and radiological evaluation revealed occurrence of new bone metastases in six patients (Group II), with concurrent significant increase in concentrations of urine DPD and Ca+2 (p=0.006 for Ca+2 and p=0.009 for DPD, respectively). Urine Ca+2 and DPD levels can be used for assessment of response of bone to local irradiation, and are able to predict further progression of bone metastases in cancer patients.en_US
dc.identifier.endpage559en_US
dc.identifier.issn0392-9078
dc.identifier.issue4en_US
dc.identifier.pmid18365552en_US
dc.identifier.scopus2-s2.0-38549083675en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage553en_US
dc.identifier.urihttps://hdl.handle.net/11616/94439
dc.identifier.volume26en_US
dc.identifier.wosWOS:000252566100017en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBiomed Central Ltden_US
dc.relation.ispartofJournal of Experimental & Clinical Cancer Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecturine calciumen_US
dc.subjectdeoxypyridinolineen_US
dc.subjectpalliative radiotherapyen_US
dc.titleUrine calcium and deoxypyridinoline in assessment of response to local radiation therapy for metastatic bone diseaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu